Sinopharm, a pharmaceutical group based in Shanghai, had been developing two vaccine doses. Currently, human trials involving nearly 350,000 people are ongoing in Argentina, Bahrain, Peru, the United Arab Emirates, and several others. China is among the few coronavirus vaccine developers promising an effective cure by the end of the year. They have also committed to distributing their vaccines to several countries, prioritizing low-income nations.
In Bahrain, phase three of the trials began recruiting 6,000 participants. Since June, phase three in the U.A.E. recruited 15,000 participants.
Around 1,000 volunteers are receiving the two-dose vaccine per day. According to the company, the vaccine may provide immunity for up to three years.
The commitment to providing vaccines to developing countries comes from the collaborative group COVID-19 Vaccine Global Access (COVAX), which China officially joined on October 8. COVAX aims to provide two billion doses of Covid-19 vaccines to vulnerable people and healthcare frontliners in developing countries. Around 80 countries have joined the alliance alongside the World Health Organization, the Coalition for Epidemic Preparedness Innovations, and Gavi, the Vaccine Alliance owned by the Bill & Melinda Gates Foundation.
China has a total of four vaccines that are in the third stage of clinical testing worldwide. The other leading vaccines are being developed by the companies Sinovac and CanSino Biologics.
According to trial results, only 1% to 3% of participants experienced fever from Sinovac’s vaccine candidate. No more than 8% experienced exhaustion, and 10% experiencing pain. There were no severe adverse events reported.
The commitment to providing vaccines to developing countries comes from the collaborative group COVID-19 Vaccine Global Access (COVAX), which China officially joined on October 8. COVAX aims to provide two billion doses of Covid-19 vaccines to vulnerable people and healthcare frontliners in developing countries. Around 80 countries have joined the alliance alongside the World Health Organization, the Coalition for Epidemic Preparedness Innovations, and Gavi, the Vaccine Alliance owned by the Bill & Melinda Gates Foundation.
China has a total of four vaccines that are in the third stage of clinical testing worldwide. The other leading vaccines are being developed by the companies Sinovac and CanSino Biologics.
According to trial results, only 1% to 3% of participants experienced fever from Sinovac’s vaccine candidate. No more than 8% experienced exhaustion, and 10% experiencing pain. There were no severe adverse events reported.
Originally published by ScienceTimes